T-Cell
Showing 9976 - 10000 of >10,000
Clear Cell Renal Cell Carcinoma Trial in Duarte, Nashville (XmAb819)
Recruiting
- Clear Cell Renal Cell Carcinoma
- XmAb819
-
Duarte, California
- +1 more
Jun 20, 2022
MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)
Active, not recruiting
- Myelodysplastic Syndromes
- cyclophosphamide, fludarabine, and antithymocyte globulin
-
Seoul, Korea, Republic ofAsan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023
The Clinical Manifestations of Severe Acute Respiratory
Completed
- Covid19
-
Assiut, EgyptAssiut University Hospital
Jun 5, 2022
Prostate Cancer, Endometrial Cancer Trial in Chicago (Rucaparib, Nivolumab)
Terminated
- Prostate Cancer
- Endometrial Cancer
-
Chicago, IllinoisUniversity of Chicago Medical Center
Feb 15, 2021
High Grade Meningioma Trial in Boston (Pembrolizumab)
Active, not recruiting
- High Grade Meningioma
-
Boston, Massachusetts
- +1 more
Jul 29, 2021
Shigellosis Trial in Baltimore (Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose, Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses, Vaccine: 2.6±0.8
Completed
- Shigellosis
- Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose
- +4 more
-
Baltimore, Maryland
- +1 more
Aug 10, 2021
Esophagus Cancer Trial in Anyang, Luoyang (CRT, surgery)
Unknown status
- Esophagus Cancer
- CRT
- surgery
-
Anyang, Henan, China
- +1 more
Dec 1, 2020
Stunting, Low Birth Weight, Anemia in Pregnancy Trial in Quetta, Karachi (Maamta (Nutritious Food Supplement), Wawamum
Completed
- Stunting
- +2 more
- Maamta (Nutritious Food Supplement)
- Wawamum (Lipid-Based Nutrient Supplement)
-
Quetta, Balochistan, Pakistan
- +1 more
Jul 19, 2021
Multiple Sclerosis Trial in Muenster (311 nm narrowband UVB irradiation)
Recruiting
- Multiple Sclerosis
- 311 nm narrowband UVB irradiation
-
Muenster, NRW, GermanyUniversity Hospital Muenster
Nov 16, 2022
3D-MRE for Assessing Cirrhosis and Portal Hypertension
Not yet recruiting
- Cirrhosis, Liver
- Portal Hypertension
- 3D-MRE
- HVPG
- (no location specified)
Jul 26, 2022
Idiopathic Membranous Nephropathy Trial (Rituximab, Cyclophosphamide)
Not yet recruiting
- Idiopathic Membranous Nephropathy
- (no location specified)
Aug 22, 2022
Osimertinib for NSCLC With Uncommon EGFR Mutations
Enrolling by invitation
- Carcinoma, Non-Small-Cell Lung
- Genes, erbB-1
-
Ramat Gan, IsraelSheba Medical Centre
Jun 14, 2022
Immunological Heterogeneity of Tumor Microenvironment in
Recruiting
- Stomach Cancer
-
Fuzhou, Fujian, ChinaDepartment of Gastric Surgery
Apr 12, 2021
CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)
Recruiting
- CD20-positive B-cell Non-Hodgkin's Lymphoma
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023
Diabetes, Diabetes, Type 1, Glucose Metabolism Disorders Trial in Edmonton, Vancouver, Toronto (VCTX210A unit)
Recruiting
- Diabetes Mellitus
- +6 more
- VCTX210A unit
-
Edmonton, Alberta, Canada
- +2 more
Apr 1, 2022
Pain, Postoperative, Excavatum, Pectus, Scoliosis Idiopathic Trial in Cincinnati (Meditation)
Enrolling by invitation
- Pain, Postoperative
- +2 more
- Meditation
-
Cincinnati, OhioCincinnati Childrens Hospital Medical Center
Dec 7, 2022
Tubal Pregnancy Unruptured Trial in Krakow (Letrozole as monotherapy, MTX as monotherapy)
Active, not recruiting
- Tubal Pregnancy Unruptured
- Letrozole as monotherapy
- MTX as monotherapy
-
Krakow, PolandJagiellonian University Medical College, Department of Gynecolog
Apr 29, 2023
Fever of Unknown Origin (FUO) in Elderly Patients
Recruiting
- Fever of Unknown Origin
- observational study
-
Brussel, Jette, BelgiumUZ brussel
Jan 30, 2023
Esophageal Cancer by AJCC V8 Stage Trial in Zhengzhou (Camrelizumab+Apatinib+Chemotherapy?Camrelizumab+Apatinib,
Recruiting
- Esophageal Cancer by AJCC V8 Stage
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Feb 12, 2023
Bone Marrow Disease, Hematological Malignancy Trial in Kayseri (Musictherapy)
Active, not recruiting
- Bone Marrow Disease
- Hematological Malignancy
- Musictherapy
-
Kayseri, TurkeyKayseri City Hospital
Jun 8, 2023
Allergic Asthma, Allergic Rhinoconjunctivitis, Immune Tolerance Trial in Lørenskog (Andosan, Placebo)
Recruiting
- Allergic Asthma
- +2 more
- Andosan
- Placebo
-
Lørenskog, Viken, NorwayAkershus university hospital
Dec 31, 2021